Biohaven (BHVN) Competitors

Moderna (NASDAQ:MRNA) and Biohaven (NYSE:BHVN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, community ranking, dividends, analyst recommendations, institutional ownership and media sentiment.

Does the MarketBeat Community prefer MRNA or BHVN?

Biohaven received 188 more outperform votes than Moderna when rated by MarketBeat users. Likewise, 67.11% of users gave Biohaven an outperform vote while only 55.35% of users gave Moderna an outperform vote.

Company	Underperform	Outperform
Moderna	Outperform Votes 212 55.35%	Underperform Votes 171 44.65%
Biohaven	Outperform Votes 400 67.11%	Underperform Votes 196 32.89%

Do institutionals & insiders have more ownership in MRNA or BHVN?

75.3% of Moderna shares are held by institutional investors. Comparatively, 88.8% of Biohaven shares are held by institutional investors. 15.7% of Moderna shares are held by company insiders. Comparatively, 16.0% of Biohaven shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Do analysts recommend MRNA or BHVN?

Moderna presently has a consensus target price of $79.50, suggesting a potential upside of 90.01%. Biohaven has a consensus target price of $63.00, suggesting a potential upside of 52.03%. Given Moderna's higher possible upside, research analysts clearly believe Moderna is more favorable than Biohaven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	4 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.14
Biohaven	0 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	3.07

Is MRNA or BHVN more profitable?

Biohaven has a net margin of 0.00% compared to Moderna's net margin of -43.77%. Moderna's return on equity of -17.68% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-43.77%	-17.68%	-13.35%
Biohaven	N/A	-225.12%	-158.89%

Does the media favor MRNA or BHVN?

In the previous week, Moderna had 12 more articles in the media than Biohaven. MarketBeat recorded 23 mentions for Moderna and 11 mentions for Biohaven. Biohaven's average media sentiment score of 1.02 beat Moderna's score of 0.34 indicating that Biohaven is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	8 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biohaven	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, MRNA or BHVN?

Moderna has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500. Comparatively, Biohaven has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500.

Which has stronger earnings and valuation, MRNA or BHVN?

Biohaven has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$5.06B	3.18	-$4.71B	-$5.82	-7.19
Biohaven	$462.51M	9.06	-$408.17M	-$9.35	-4.43

Summary

Biohaven beats Moderna on 11 of the 18 factors compared between the two stocks.